US Patent 7495017 Phosphodiesterase 4 inhibitors
Patent 7495017 was granted and assigned to Memory Pharmaceuticals on February, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 17 Sep, 2023
Golden AI
Edits made to:
Infobox (+4 properties)
Infobox
Patent Inventor Names
Allen Hopper0
Erik Kuester0
Richard Conticello0
Robert Dunn0
Edits on 15 Sep, 2023
Golden AI
Edits made to:
Article (+257 characters)
Article
Patent abstract
Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.
Edits on 25 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 19 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07495017 Phosphodiesterase 4 inhibitors US Patent 7495017 Phosphodiesterase 4 inhibitors
Infobox
Patent Number
074950170
Patent Number
74950170
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
074950170
Date of Patent
February 24, 2009
0Patent Application Number
117971510
Date Filed
May 1, 2007
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 1 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07495017 Phosphodiesterase 4 inhibitors
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07495017
Date of patent
February 24, 2009
Patent application number
11797151
Date Filed
May 1, 2007
Patent primary examiner
Find more entities like US Patent 7495017 Phosphodiesterase 4 inhibitors
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.